Animal models of herpes simplex virus immunity and pathogenesis.
Herpes simplex viruses are ubiquitous human pathogens represented by two distinct serotypes: herpes simplex virus (HSV) type 1 (HSV-1); and HSV type 2 (HSV-2). In the general population, adult seropositivity rates approach 90% for HSV-1 and 20-25% for HSV-2. These viruses cause significant morbidity, primarily as mucosal membrane lesions in the form of facial cold sores and genital ulcers, with much less common but more severe manifestations causing death from encephalitis. HSV infections in humans are difficult to study in many cases because many primary infections are asymptomatic. Moreover, the neurotropic properties of HSV make it much more difficult to study the immune mechanisms controlling reactivation of latent infection within the corresponding sensory ganglia and crossover into the central nervous system of infected humans. This is because samples from the nervous system can only be routinely obtained at the time of autopsy. Thus, animal models have been developed whose use has led to a better understanding of multiple aspects of HSV biology, molecular biology, pathogenesis, disease, and immunity. The course of HSV infection in a spectrum of animal models depends on important experimental parameters including animal species, age, and genotype; route of infection; and viral serotype, strain, and dose. This review summarizes the animal models most commonly used to study HSV pathogenesis and its establishment, maintenance, and reactivation from latency. It focuses particularly on the immune response to HSV during acute primary infection and the initial invasion of the ganglion with comparisons to the events governing maintenance of viral latency.
Department of Microbiology and Immunology, Drexel University College of Medicine, 245 North 15th Street, Philadelphia, PA, 19102, USA.
Christina M
CM
Kollias
Richard B
RB
Huneke
Brian
B
Wigdahl
Stephen R
SR
Jennings
D000818:Animals; D002490:Central Nervous System / Q000473:pathology / Q000821:virology*; D004195:Disease Models, Animal; D018792:Encephalitis, Viral / Q000473:pathology* / Q000821:virology; D017950:Ganglia, Sensory / Q000473:pathology / Q000821:virology*; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000473:pathology* / Q000821:virology; D006561:Herpes Simplex / Q000473:pathology* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000472:pathogenicity* / Q000502:physiology; D018258:Herpesvirus 2, Human / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D007113:Immunity, Innate; D051379:Mice; D011817:Rabbits; D013045:Species Specificity; D014775:Virus Activation; D017735:Virus Latency